Kaplan–Meier analyses revealed that GBP5 upregulation shows a poor disease-free survival rate in the GSE4922 breast cancer cohort, unfavorable recurrence-free survival probabilities in the GSE9195 and GSE1379 breast cancer cohorts and a shorter time period of brain metastasis in the GSE12276 breast cancer cohort (Figure 2A–D). Here, GBP5 is linked to breast cancer.